title: Mirtazapine-induced worsening of restless legs syndrome (RLS) and ropinirole-induced psychosis: challenges in management of depression in RLS.
authors.affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA. chopra.amit@mayo.edu
authors.forename: Amit
authors.initials: A
authors.lastname: Chopra
authors.forename: Dahlia Saad
authors.initials: DS
authors.lastname: Pendergrass
authors.forename: J Michael
authors.initials: JM
authors.lastname: Bostwick
mesh_terms: D000369:Aged, 80 and over; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078785:Mirtazapine; D011605:Psychoses, Substance-Induced / Q000150:complications / Q000209:etiology*; D012148:Restless Legs Syndrome / Q000139:chemically induced* / Q000150:complications
chemical_list: D000929:Antidepressive Agents, Tricyclic; D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole; D008803:Mianserin; D000078785:Mirtazapine